Duration of Antibiotic Treatment in Community-acquired Pneumonia

Overview

International and national clinical guidelines recommend short antibiotic regimens in patients with non-severe community-acquired pneumonia (CAP) who have reached clinical stability. However, adherence to these recommendations remains unclear. The goals of this quasi-experimental trial are: 1) to assess adherence to clinical guidelines in relation to the duration of antibiotic treatment in patients hospitalized for non-severe CAP who have reached clinical stability; 2) increase adherence to clinical guidelines and reduce the use of antibiotics in patients hospitalized for non-severe CAP who have achieved clinical stability after at least 5 days of antibiotic treatment. To this end, a multicenter prospective study will be carried out over 2 years and divided into 2 phases: i) during the first year (observational phase), patients with CAP hospitalized in the participating centers will be recorded to assess objective 1; ii) to achieve objective 2, at the beginning of the second year (quasi-experimental trial) the centers will be randomized into 2 groups of hospitals, one of them a control group and the other an intervention group. The intervention will consist in automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability.

Full Title of Study: “Adherence to Clinical Guidelines Regarding the Duration of Antibiotic Treatment in Patients Hospitalized for Community-acquired Pneumonia With Clinical sTability. ADAPT Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: Single (Participant)
  • Study Primary Completion Date: June 2025

Interventions

  • Behavioral: Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia
    • Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability

Arms, Groups and Cohorts

  • No Intervention: Standard of care
    • Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.
  • Other: Interventional
    • Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability

Clinical Trial Outcome Measures

Primary Measures

  • Duration of antibiotic treatment
    • Time Frame: 90 days
    • Total duration in days of antibiotic treatment (including the days of outpatient antibiotic prescribed at discharge).

Secondary Measures

  • Duration of antibiotic treatment after reaching clinical stability
    • Time Frame: 90 days
    • Duration in days of antibiotic treatment after reaching clinical stability
  • Patients treated with an adequate duration of 5±1 days
    • Time Frame: 90 days
    • Percentage of patients treated with an adequate duration of 5±1 days
  • Patients admitted to the ICU after the 5th day
    • Time Frame: 90 days
    • Percentage of patients admitted to the ICU after the 5th day of admission
  • Mortality
    • Time Frame: 90 days
    • Percentage of patients who died during the study
  • Readmission
    • Time Frame: 90 days
    • Percentage of patients who are readmitted after hospital discharge
  • Reintroduction of antibiotic treatment
    • Time Frame: 90 days
    • Percentage of patients with reintroduction of antibiotic treatment
  • Length of hospital stay
    • Time Frame: 90 days
    • Length of hospital stay in days
  • Adverse events related to antibiotic treatment
    • Time Frame: 90 days
    • Percentage of patients with adverse events related to antibiotic treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Patients >18 years hospitalized for community-acquired pneumonia with a new infiltrate on chest X-ray and/or computerized tomography. – At least one compatible sign or symptom (fever, cough, expectoration, dyspnea, chest pain or crackles on auscultation) – Correctly treated with ≥ 3 days of antibiotic Exclusion Criteria:

  • Intensive care unit admission during the first 5 days since hospital admission – Abscess or necrotizing pneumonia – Empyema or pleural effusion requiring drainage tube – Bronchiectasis – Cystic fibrosis – Active tuberculosis – Postobstructive pneumonia – Suspected bronchial aspiration – SARS-CoV-2 infection – Immunosuppression (congenital immunodeficiencies, HIV infection, solid organ transplantation, functional or anatomical asplenia, immunosuppressive treatment, active solid or haematological neoplasia [active treatment in the last 12 months], etc.) – Hospital acquired pneumonia – Concomitant extrapulmonary infection that requires antibiotic treatment for more than 5 days (eg myocarditis) – Confirmed diagnosis alternative to pneumonia (eg, lung cancer)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Instituto de Investigacion Sanitaria La Fe
  • Collaborator
    • Instituto de Salud Carlos III
  • Provider of Information About this Clinical Study
    • Principal Investigator: Raúl Méndez, MD PhD, Dr. – Instituto de Investigacion Sanitaria La Fe
  • Overall Official(s)
    • Raúl Méndez, MD, PhD, Principal Investigator, Instituto de Investigación Sanitaria La Fe
  • Overall Contact(s)
    • Raúl Méndez, MD, PhD, +34 961244000, rmendezalcoy@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.